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Abstract
Background: Urinary incontinence is an important health problem to the individual sufferer and to health services.
Stress and stress predominant mixed urinary incontinence are increasingly managed by surgery due to advances in
surgical techniques. Despite the lack of evidence for its clinical utility, most clinicians undertake invasive urodynamic
testing (IUT) to confirm a functional diagnosis of urodynamic stress incontinence before offering surgery for this
condition. IUT is expensive, embarrassing and uncomfortable for women and carries a small risk. Recent systematic
reviews have confirmed the lack of high quality evidence of effectiveness.
The aim of this pilot study is to test the feasibility of a future definitive randomised control trial that would address
whether IUT alters treatment decisions and treatment outcome in these women and would test its clinical and
cost effectiveness.
Methods/design: This is a mixed methods pragmatic multicentre feasibility pilot study with four components:-
(a) A multicentre, external pilot randomised trial comparing basic clinical assessment with non-invasive tests and
IUT. The outcome measures are rates of recruitment, randomisation and data completion. Data will be used to
estimate sample size necessary for the definitive trial.
(b) Qualitative interviews of a purposively sampled sub-set of women eligible for the pilot trial will explore
willingness to participate, be randomised and their overall trial experience.
(c) A national survey of clinicians to determine their views of IUT in this context, the main outcome being their
willingness to randomise patients into the definitive trial.
(d) Qualitative interviews of a purposively sampled group of these clinicians will explore whether and how they
use IUT to inform their decisions.
Discussion: The pilot trial will provide evidence of feasibility and acceptability and therefore inform the decision
whether to proceed to the definitive trial. Results will inform the design and conduct of the definitive trial and
ensure its effectiveness in achieving its research aim.
Trial registration number: Current Controlled Trials ISRCTN71327395 assigned 7th June 2010.
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Background
Scientific background
Urinary incontinence (UI) can dramatically influence the
physical, psychological and social wellbeing of affected
individuals, their families and carers and has considerable
resource implications for the health service. The esti-
mated prevalence of UI in general population studies var-
ies from 5% to 69% with most estimates between 25%
and 45%. In middle aged and older women daily inconti-
nence estimates vary from 5% to 15% [1]. The majority of
these women have stress urinary incontinence (SUI),
50%, or mixed urinary incontinence (MUI), 36% [2]. A
2004 UK study estimated the annual cost to the National
Health Service of treating clinically important UI in
women at £233m [3].
Urodynamic testing is one of several methods that may
be used in the assessment of UI to guide management
decisions, including whether surgical intervention is indi-
cated. This group of investigations is used to evaluate the
function of the lower urinary tract and can be invasive
(requiring catheterisation) or non-invasive [4]. The most
commonly used invasive urodynamic test (IUT) is multi-
channel cystometry; [5] this looks at the pressure/volume
relationships during bladder filling and emptying, with a
view to defining a functional, as distinct from symptomatic,
diagnosis. Whilst this is the most commonly used IUT,
videocystometry and ambulatory bladder pressure moni-
toring are also used. Non-invasive tests include frequency/
volume charting, mid-stream urine culture, urine flow rate
and residual urine volume measurement by ultrasound [6].
The current position of IUT in the diagnostic pathway is
not agreed, and practice varies considerably. In a UK sur-
vey in 2002 only half of the units surveyed had guidelines
on indications for the tests, and 84.5% carried out cystome-
try in all women with incontinence [5]. Current guidance
from the National Institute for Health and Clinical Excel-
lence (NICE) suggests that cystometry is not required prior
to conservative treatments, and that there is no evidence to
support its use prior to surgery where the diagnosis of SUI
is likely [7]. NICE, the National Institute for Health
Research - Health Technology Assessment (NIHR-HTA)
programme, the Cochrane Collaboration and the Interna-
tional Consultations on Incontinence (ICI) have all recently
undertaken systematic reviews on the subject of urody-
namic testing, and all emphasize the lack of high quality
primary research confirming clinical utility [4,7-10].
Patients and clinicians working together in a project asso-
ciated with the James Lind Alliance (JLA) have identified
IUT as a research priority and, along with NICE, have
recommended further research to answer the question of
whether the use of IUT, prior to initial or subsequent treat-
ments, affects the outcomes and cost effectiveness of inter-
ventions in women with UI [7,10].
The costing report associated with the NICE clinical
guideline on UI used an estimated charge of £176 for
each IUT. Consequently, the annual potential saving
from eliminating IUT prior to conservative treatment
was estimated at approximately £3 m and savings from
a more rational use of IUT before surgery for SUI at
approximately £321,000 [7]. These calculations are
based on 2002 -2007 figures. Changes in available opera-
tive techniques have led to dramatic alterations in surgi-
cal practice as recorded in the NHS’s Hospital Episode
Statistics (HES) which showed a 54% increase in surgery
for SUI over the last ten years [11]. These data along
with 2008-09 national tariff costs for IUT of £425 sug-
gest that the savings from a more rational use of IUT
prior to surgery are likely to be substantially greater.
A randomised controlled trial (RCT) of IUT versus
less invasive procedures prior to surgery would provide
gold-standard evidence of the clinical and cost-effective-
ness of this expensive procedure. However, prior to pro-
ceeding to a full scale RCT, a feasibility pilot study is
deemed necessary for several reasons;
The use of IUT is widely established in clinical practice;
many experts consider it a mandatory investigation, parti-
cularly prior to surgery [12,13]. So we need to establish
whether sufficient clinicians are in equipoise and willing to
recruit and randomise patients to a RCT. There is growing
evidence in favour of pilot studies involving collection of
both quantitative and qualitative data prior to embarking
on this type of definitive RCT [14].
Patients may not see the importance of ‘testing a test’
and are usually willing to undergo even invasive investi-
gations in the belief that they guide their clinician and
themselves to the most appropriate management. Trials
reported in 2000 and 2001 randomizing radiography
investigations for low back pain were only able to recruit
23% and 51% of patients approached to enter the rando-
mised arms [15,16]. By assessing patients’ willingness to
undergo randomisation, potential barriers and facilitators
to participation can be identified and used to modify the
design of the definitive trial.
Given these uncertainties, before carrying out a defini-
tive trial, it is essential to undertake a pilot study to esti-
mate the extent of the potential recruitment problems
described above and to provide robust estimates of the
variability of the proposed outcome measures and of the
likely rates of eligibility, recruitment, randomisation and
retention of participants.
Specific objectives
The future definitive trial (INVESTIGATE II)
The objective of the proposed future definitive trial is to
address the question of whether IUT compared to basic
clinical assessment (non-invasive) alters treatment
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decisions and outcomes, including the incremental cost
per quality adjusted life year (QALY) gained, in women
potentially suitable for surgical treatment of SUI or
stress predominant MUI. The outcome measures will
include quantified post-treatment urinary leakage,
impact on general health and condition-specific quality
of life, adverse effects from investigation or treatment,
and health economic outcomes. The latter will include
mean incremental cost, mean incremental QALYs, and
incremental cost per QALY. Thus, in the definitive trial,
we hope to establish whether IUT should indeed be
offered to all women prior to surgery.
The pilot trial (INVESTIGATE I)
The objective of this pilot trial is to test the logistics and
feasibility of the definitive trial, specifically;
● To carry out an external (rehearsal) pilot trial ran-
domising patients between basic assessment and IUT to
assess patient recruitment and willingness to be rando-
mised, rehearse methodology, and provide outcome data
to inform sample size calculations for a definitive trial.
● To explore women’s reasons for participation or
non-participation and their experiences of the pilot trial
procedures. Their responses may help not only in the
evaluation of the feasibility of the definitive trial, but
also in the planning and optimising of future recruit-
ment and retention.
● To assess clinicians’ views on IUT in this particular
context and their willingness to randomise patients
within a definitive trial.
Methods/Design
Trial design
The pilot feasibility study is a mixed methods pragmatic
multicentre study [17] with four components, conducted
over a two year period, as follows:-
1. A multicentre randomised external pilot trial com-
paring basic clinical assessment and IUT. The design
fully rehearses the research design and outcome mea-
sures proposed for the definitive RCT.
2. Qualitative interviews with a purposely sampled
subset of women eligible for the trial to explore their
reasons for agreeing (or not) to participate, their willing-
ness to be randomised, and their experiences of the pilot
trial.
3. A national web-based survey of relevant clinicians’
views about urodynamics and their willingness to enter
their patients into the definitive trial; the membership
lists of the appropriate professional bodies and special
interest groups will be used as the sampling frame.
4. Qualitative interviews with a small subset of clini-
cians (respondents to the survey) to explore whether
and how they use the results of IUT to inform their
decisions, and to contextualise the questionnaire
responses.
Randomised trial
Participants
Women will be recruited from six UK units which include
a mix of specialist urogynaecology (Newcastle upon Tyne
Hospitals NHS Foundation Trust & University Hospitals
of Leicester NHS Trust), female urology (Morriston Hos-
pital, Swansea & Royal Hallamshire Hospital, Sheffield)
and general gynaecology (Queen Elizabeth Hospital,
Gateshead & Wansbeck Hospital, Northumberland)
departments. These units provide secondary +/- tertiary
level of care and are representative of the UK units
who would be invited to participate in the definitive trial.
Eligibility criteria for the pilot trial are those anticipated
for the future definitive trial.
Inclusion criteria
Women fulfilling the following characteristics
● With a clinical diagnosis of SUI or stress predomi-
nant MUI
● Who consider that their family is complete
● Who have undergone a course of pelvic floor mus-
cle training (+/- other non surgical treatments for their
urge symptoms) with inadequate resolution of
symptoms
● Both the woman herself and her treating clinician
should agree that surgery is an appropriate and accepta-
ble next line of treatment.
Exclusion criteria
● Symptomatic utero-vaginal prolapse requiring
treatment
● Previous surgery for urinary incontinence or pelvic
organ prolapse
● Urodynamic investigation within the last three years
● Neurological disease causing urinary incontinence
● Current involvement in competing research studies
● Unable or unwilling to give informed consent
Over a nine-month recruitment period, assigned
research nurses will identify and obtain consent from
eligible patients. The outpatient clinics run by each unit
will be the source of potential recruits. Notes will be
screened prior to the appointment and a patient infor-
mation sheet posted with the appointment letter if, in so
far as can be judged from records alone, the patient
meets eligibility criteria. This will allow any questions
that the woman may have to be addressed within the
forthcoming clinic visit. Informed, written consent will
be taken from those who agree to take part.
A small number may be identified only at the time of
attendance at the clinic. They will be invited to partici-
pate and given the relevant information. The research
nurse will contact the patient after a period of at least
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24 hours, respond to any questions they may have and
review their decision regarding involvement.
Consent to retain contact details will be obtained from
those declining recruitment into the pilot trial but who
are willing to be contacted for the qualitative interviews.
Participants will be informed prior to recruitment that
they can withdraw at any stage of the research without
having to provide a reason and that withdrawal will not
affect the care they receive.
Randomisation
Patients who have given consent will be randomised 1:1
to either the control or intervention arm, by an inter-
net-accessed system operated by the Newcastle Clinical
Trials Unit. Randomisation will be stratified by centre,
using a random block length to minimise the risk of
breech of concealment of allocation.
Blinding
Due to the nature of this trial it is not possible to blind
participants and clinicians after randomisation.
Intervention and control conditions
Control arm
Participants will undergo basic clinical assessment supple-
mented by non-invasive tests as directed by the clinician.
These may include frequency/volume charting, mid-
stream urine culture, urine flow rate and residual urine
volume measurement by ultrasound; they will not undergo
invasive urodynamic testing. Subsequently, if agreed to by
the clinician and the patient, they will undergo surgical
treatment. Given the pragmatic nature of the study the
choice of operation will be left to the individual surgeon
and patient.
Intervention arm
Participants will undergo assessment as above and will also
undergo invasive urodynamic testing. Usually this will be
multi-channel cystometry; however, videourodynamics
and long-term ambulatory bladder pressure monitoring
may also be included at the discretion of the clinician.
Women will undergo similar surgical treatment if uro-
dynamic stress incontinence (USI) is confirmed on IUT.
This will comprise the majority of women. Where other
diagnoses are identified they will be offered alternative
treatments according to current NICE recommenda-
tions.5 In some cases, where mixed abnormalities are
reported, women may first undergo one or more of these
treatments and then proceed to surgery for SUI. Post-
operative follow up will be arranged in accordance with
the clinician’s usual practice.
Data collection
The questionnaires to be administered in the pilot trial are
those proposed for the definitive trial, as described below.
Following randomisation all patients will be asked to
complete baseline study outcome questionnaires.
Data will be collected from the hospital records
throughout the patient’s participation in the study to
rehearse the data collection methods for the definitive
trial. Data will include details of non-invasive and inva-
sive investigations, operative and in-patient procedures
including postoperative complications, non-surgical
treatments and resource utilisation.
Women in both arms will complete a follow-up study
outcome questionnaire six months after the first treat-
ment they receive in the trial. Questionnaire response
will be encouraged by providing prepaid envelopes and
posting one-month reminder letters.
Outcomes
The pilot trial
The outcome measures for the initial feasibility study
are:
● Number of eligible patients in each unit, and the
rates of recruitment, randomisation and data
completion.
● The confirmation or otherwise that units are able to
identify the required number of eligible women and
recruit them.
● The acceptability of the investigation strategies as
manifest though recruitment and retention levels.
● The feasibility and acceptability of data collection
tools measured by completion rates and quality of data.
● Clinical outcome data to estimate the necessary
sample size for the definitive trial.
Whilst it is not possible to be categorical about it at this
stage, the criteria used to establish feasibility, and to con-
firm a decision to proceed with a definitive trial, will be
determined as a compound function of the above factors.
The required sample size for a subsequent definitive trial
will be calculated using the clinical outcome data from the
pilot trial. A definitive trial will be judged to be feasible if
the numbers of eligible patients recruited, randomised and
retained within the pilot trial, plus the number of surgeons
in clinical equipoise on the subject who are prepared to
randomise their patients indicate that it will be possible to
generate the required sample within a period of 24 months.
The protocol for the definitive trial will be modified to
improve recruitment based upon the findings of the
qualitative interviews with patients not randomised to
the pilot trial. Similarly, if the experiences of those
women randomised, or the study team’s experience of
the pilot indicate that protocol modifications may be of
value then these would also be considered within the
judgment of feasibility.
The definitive trial
Should we proceed to a definitive trial, the currently
favoured primary outcome is the combined symptom
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score of the International Consultation on Incontinence
Female Lower Urinary Tract Symptoms questionnaire
(ICIQ-FLUTS) at 6 months after treatment [18]. A
patient reported outcome measure has been selected
because clinician assessment of patient outcomes tends
to underestimate the patients’ perceived symptoms [19].
Secondary outcomes will include the quantification of
urinary leakage (three day bladder diary and ICIQ-UI
Short Form), the prevalence of symptomatic ‘de novo’
functional abnormalities including voiding dysfunction
and detrusor overactivity (subscales of ICIQ-FLUTS,
with cystometry in symptomatic patients), the impact of
urinary symptoms on quality of life (ICIQ-LUTSqol and
Urogenital Distress Inventory (UDI)) and utility values
from the EQ-5D questionnaire and SF-6D (utility score
generated from SF-12 questionnaire) [20]. These are
rehearsed within the pilot study with a view to refining
the choice and timing of outcomes for the main trial,
based on data yield (e.g. the percentage of recruited par-
ticipants returning completed questionnaires) and qual-
ity (e.g. the completeness and consistency of responses
within returned questionnaires).
Sample size
There is relatively little information on the distribution of
the ICIQ-FLUTS combined symptom score or on recruit-
ment, randomisation and retention rates in the relevant
patient population. As a result there are insufficient data
to calculate the sample size required in a definitive trial to
yield adequate power to detect a clinically important dif-
ference in the primary outcome measure. This is one of
the main reasons to undertake the pilot trial.
The sample size for pilot trials is typically determined
pragmatically, with recommendations of a minimum of
30 participants per arm [21]. We aim to recruit 60 per
trial arm to investigate the distribution of the outcome
measures. Previous trials in the area of pelvic floor dys-
function, including investigation, [22] surgical, [23-25]
and non-surgical treatments [26] suggest attrition rates
of 13% (7-20%) between identification and randomiza-
tion, 16% (6-20%) between randomization and treatment,
and 13% (9-20%) between treatment and follow-up at 6
months. Taking the more pessimistic figure in each case
we estimate that a total of 240 eligible patients should be
approached allowing for a 50% overall attrition. The
recruiting units collectively undertake 540 relevant pro-
cedures per year; therefore, identifying 240 eligible
women within the nine month recruitment period should
not present undue difficulty.
Results/analysis
Data will be analysed after all patients have completed
six months follow up. The statistical analysis will be
descriptive in nature and provide estimates of key trial
variables for the definitive trial to inform power calcula-
tions and other aspects of the trial design. The cost-uti-
lity analysis will be rehearsed which may inform the
study hypothesis for the definitive trial as well as
informing the analysis plan.
Qualitative interviews with women eligible for
the randomised trial
Participants
A sample of women approached to participate in the
pilot trial will be invited to take part in the qualitative
interviews. Purposive sampling will be used to include
women from a range of ages, trial participation status
(did not agree to participate, agreed to participation and
retained to follow-up, agreed to participation but pro-
vided incomplete follow up data), allocation status (IUT
or basic assessment), treatment received (surgery or
conservative), and study site.
Intervention
The selected women will receive a postal invitation from
the Newcastle Clinical Trials Unit. If they are interested
in participating, they will be asked to return an enclosed
expression of interest form. Arrangements for the inter-
view will then be made. Women declining participation
into the pilot trial will be approached as soon as possible
after that decision; those participating in the trial will be
approached at the end of their participation in the trial to
capture their overall experience.
Written, informed consent will be taken prior to the
interview. An expert qualitative interviewer will conduct
the interviews which, with permission, will be audio-
recorded and transcribed verbatim. Interviews will be
semi-structured using a prompt guide with broad topic
areas but emphasis will be on discussing the women’s
own perspectives freely. The prompt guide has been
developed using a combination of the background litera-
ture and expert qualitative research experience. It may
be modified, if necessary, as the interviews progress to
incorporate issues raised by interviewees that have not
been anticipated but are of interest [27]. It is anticipated
that 25-30 interviews will be required, but data collec-
tion will continue until a point of theoretical saturation
has been reached [28,29].
Results/Analysis
The aims of the interviews are to explore women’s
understanding and experience of the study, their deci-
sions around participation and their perceived barriers
to and facilitators of participation.
Their responses may help not only in the evaluation of
the feasibility of a definitive trial, but also in the
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planning and optimising of recruitment and retention
e.g. to refine the content of information, recruitment
and data collection procedures used.
Both data collection and analysis will be iterative. Data
will be analysed using the constant comparative method,
[29] supported by NVivo software [30].
National clinician survey
Participants
All members of the British Society of Urogynaecology
(BSUG) and British Association of Urological Surgeons
Section of Female, Neurological and Urodynamic Urology
(BAUS-SFNUU) with current email addresses on the
membership database of the respective organisations will
be involved. Apart from a few exceptions, clinicians are
only members of one society. These urologists and gynae-
cologists are the intended source of patient recruitment
for the definitive trial and reviews indicate that endorse-
ment by respected authorities is a factor in enhancing
response rates in postal and self-completion surveys
[31-34].
Intervention
Members will be invited by email, sent from the society
secretariat, with the support of the research committees
of the aforementioned societies, to complete either a
web-based (‘http://SurveyMonkey.com’) or paper-based
questionnaire; this support has already been obtained
from both societies. Reminders will be sent three and six
weeks after initial contact to encourage and stimulate
response [31,32,34]. The data set will be closed and pre-
pared for analysis twelve weeks after initial contact as
experience in previous surveys shows that the majority of
responses are made within this period. This survey
approach will enable collection of data from a large sam-
ple of respondents over a wide geographical area in a
timely and efficient manner.
The survey questionnaire will contain both open and
closed questions and will ask for the respondent’s views
about, access to, and current use of IUT. Part of the
survey will include brief details of the proposed defini-
tive trial in the form of a ‘vignette’ and will seek to
ascertain the clinician’s willingness to participate and
randomise their patients within such a trial. The ques-
tionnaire will be piloted on non-members to assess
comprehensibility and content validity.
Results/analysis
The method of statistical analysis will be descriptive in
nature. Data will be collected on the strength of sur-
geons’ views for the necessity of invasive dynamic test-
ing for a set of vignettes using an 11-point Likert scale.
These distributions will be summarised by their med-
ians, quartiles and range. Other variables such as their
willingness to take part in a future randomised trial and
views on the importance of the questions will be sum-
marised by percentages in each category.
Qualitative clinician interviews
Participants/intervention/analysis
Clinicians participating in the national survey will be
invited, at the same time, to take part in this interview.
If they accept they will be asked to return an expression
of interest form with their contact details.
A purposive sample of these clinicians will undergo a
short telephone interview to explore their interpretation of
IUT and how they use the results to decide on the most
appropriate treatment options. Twelve interviews should
ensure that a range of views are represented (e.g. those
who do and do not currently use IUT, those who do and
do not feel is it an important part of their decision making
and those who would or would not be willing to partici-
pate in a later trial), but data collection will continue until
a point of theoretical saturation is reached [27].
Telephone interviews enable this to be done effi-
ciently. Electronic, written consent will be obtained
prior to the interview.
Analysis will identify key themes related to the use of
IUT and possible involvement in a later trial.
Trial governance
A favourable ethical opinion for this research has been
received from Newcastle and North Tyneside No1
Research Ethics committee (reference10/H0906/76).
The operational management of the trial will be over-
seen by a Trial Management Group that has responsibil-
ity for ensuring the compliance and progress of the
study in relation to all regulatory, administrative, aca-
demic and clinical/safety issues.
The Data Monitoring and Ethics Committee (DMEC)
will focus on the safety and ethical issues. Their role
will be to monitor data and make recommendations on
whether or not the trial should continue for ethical or
safety reasons. DMEC membership will comprise an
independent chair, an independent statistician and one
other member, independent of the research team, with
relevant content area or methodological expertise.
The Trial Steering Committee (TSC) will provide
overall supervision for the trial on behalf of the Trial
Sponsor (Newcastle upon Tyne Hospital NHS Founda-
tion Trust) and Trial Funder (NIHR HTA) and will
ensure that the trial is conducted in accordance with
the principles of Good Clinical Practice [35]. The com-
mittee membership comprises and independent chair,
two other independent members with relevant content
area or methodological expertise, two lay members, the
chief investigator, another principal investgator, the trial
statistician, and the senior trial manager.
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R&D approval for all participating sites has been
sought, via the NIHR Coordinated System for gaining
NHS permissions (CSP); this system seeks to ensure
that all quality assurance and statutory requirements in
respect of clinical research are met, through standardis-
ing and streamlining the process for gaining NHS Per-
mission in England [36].
All data will be kept in accordance with Caldicott
Principles, [37] and will be archived at the Newcastle
Upon Tyne Hospitals NHS Foundation Trust archive
facility for ten years following the last publication from
the study.
Discussion
Pilot studies play an important role in health research. A
well-conducted pilot study with clear aims and objectives
encourages methodological rigour, ensures that the work
is scientifically valid and publishable, and results in higher
quality RCTs [21]. Lancaster et al. produced a framework
and addressed some of the methodological reasons for
undertaking pilot studies related to RCTs [21]. Using this
framework as a guide we summarise below our justifica-
tions for undertaking a pilot study and its methodology.
The randomised external pilot trial rehearses the metho-
dology proposed for the definitive RCT. A run through of
the trial procedures on a smaller scale will practise and
identify any logistical issues that might be modified. The
number of eligible patients and rates of recruitment and
randomisation will confirm whether the required sample
size for a definitive trial could be identified and recruited.
Recruitment has implications for both timing and funding
of a definitive trial and poor recruitment is one of the
major reasons for abandoning trials early [21,38]. A RCT
to address whether IUT alters treatment decisions and
treatment outcome in women suitable for surgical treat-
ment of SUI or stress predominant MUI is likely to
require large numbers of participants and would therefore
be expensive and time-consuming. Prior to allocating
resources to such a large trial feasibility must be deter-
mined to reduce the risk of the definitive trial not being
able to recruit to time and target.
Data collection for the proposed definitive trial consists
of both clinical records data and patient self-completed
questionnaires. The outcome questionnaires rely on
patient recall over a six month period and analysis of com-
pletion rates and quality of data will not only test compre-
hensibility but guide timing of future data collection.
Several secondary outcome measures have been chosen
with a view to refining the choice on the basis of data yield
and quality. The demands of a trial are an identified bar-
rier to patient participation and refinement of the data col-
lection tools will ensure these are kept to a minimum [38].
Qualitative interviews with the women will explore their
reasons for participating, or not, and their experiences of
the trial with the potential benefit of guiding protocol
amendments such as the consent procedure and question-
naire format, to improve the recruitment process and
questionnaire responses.
The acceptability of the protocol is an important aspect
of the trial design. As mentioned previously IUT is widely
established in clinical practice and the absence of this
investigation prior to offering surgery is a potential bar-
rier to clinicians’ willingness to randomise their patients.
Clinician surveys in other urogynaecology research have
identified clinicians’ views of perceived benefit and com-
plications of the two arms as impacting participation
[14]. Women may also not see the benefit of testing a
test, believing that the results of any available test must
guide their clinician and themselves to the most appro-
priate management. Prior to embarking on a definitive
RCT we need to ensure that not only are the participants
willing to be randomised but that the clinicians are also
willing to randomise their patients. A UK national survey
of clinicians’ views on IUT in this particular context and
their willingness to randomise patients within a definitive
trial will help establish if sufficient clinicians are in equi-
poise. Qualitative interviews with a sub group of clini-
cians will help contextualise the responses. During the
qualitative interviews with the women willingness to be
randomised will also be explored.
Attempts to estimate sample size for a definitive trial
were unproductive because of uncertainty in the distribu-
tion of the key variables. The pilot study aims to collect
data on the primary outcome measure, the ICIQ-FLUTS
combined symptom score, to calculate the sample size
for a definitive trial.
The decision to proceed with the definitive trial as it is
currently envisaged will only be made if all aspects of
feasibility, including adequate patient recruitment and
clinician engagement are established. The combination
of quantitative methods (e.g. recruitment and retention
rates, percentage of clinicians in clinical equipoise) and
qualitative methods (e.g. an assessment of whether any
identified barriers to recruitment and retention could be
overcome by modifications to trial design or procedures)
will inform the decision and ensure its effectiveness in
achieving the research aim.
Currently there are two other on-going trials looking at
the clinical utility of urodynamics in similar patient
groups; the VaIUE trial (Value of Urodynamic Evaluation)
[39] and VUSIS-2 trial (Value of Urodynamics prior to
Stress Incontinence Surgery) [40]. Similar to INVESTI-
GATE-I, the ValUE study randomises women with a clini-
cal diagnosis of SUI or stress predominant MUI to either
no further assessment or IUT. In the VUSIS study all
women undergo invasive urodynamic testing. Those with
discordant clinical and urodynamic findings are rando-
mised between surgical treatment as dictated by their
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clinical assessment and individualised treatment dictated
by a combination of clinical and urodynamic results and
therefore addresses a different clinical question. Both of
these definitive trials use a non-inferiority design [41].
Whereas VUSIS does not define a non-inferiority margin
VaIUE defines a margin of 11% which we consider some-
what high and a difference that might potentially influence
the decisions of both clinicians and patients. The primary
outcome of both is based on the Urogenital Distress
Inventory (UDI) score at 12 months. Although our pri-
mary outcome is the ICIQ-FLUTS combined symptom
score we have chosen to include the UDI as an additional
secondary outcome. If we subsequently proceed to the
definitive trial, INVESTIGATE-II, assuming the other stu-
dies complete recruitment and publish their results, this
will allow easier comparison of results. While we are
encouraged to see that others look on this topic as being
an important clinical uncertainty, we remain of the opi-
nion that a feasibility study is an important step before
embarking on a definitive trial.
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